TREATMENTS &
RESEARCH

Search the
latest
treatment
information
here.

Dr. Huntley's
Diagnosis
Checklist

Have a symptom?
See what questions
a doctor would ask.

Next Prev

Diseases » Atrial Fibrillation » Research

Cure Research for Atrial Fibrillation

Medications currently used in research into the treatment of Atrial Fibrillation:

Note:You must always seek professional medical advice about any treatment or change in treatment plans.

Some of the different medications being used in the research into treatment of Atrial Fibrillation include:

Clonidine
Apo-Clonidine
Catapres
Catapres-TTS
Combipres
Dixarit
Duraclon
Novo-Clonidine
Nu-Clonidine

Latest Treatments for Atrial Fibrillation

Some of the more recent treatments for Atrial Fibrillation include:

Treatments for Atrial Fibrillation

Treatments to consider for Atrial Fibrillation may include:

Medical Research Breakthroughs and Atrial Fibrillation

Atrial Fibrillation in women taking drugs for oesteoporosis: New research in the US shockingly reveals that women who had taken Merck's bisphosphonate drug Fosamax (alendronate) to combat the bone-thinning disease osteoporosis, are twice as likely to develop chronically irregular heartbeat (atrial fibrillation) as opposed to those who don't take it. More than 700 female Group Health patients whose atrial fibrillation was first detected during a three-year period were studied and were matched with over 900 randomly selected female controls who did not have the condition. The controls were also from Group Health and matched the intervention group on age and presence and absence of high blood pressure. Results showed that more women with atrial fibrillation than controls had ever used alendronate (6.5 per cent or 47 women versus 4.1 per cent or 40 women, respectively; p=0.03). Also women who had ever used alendronate had an 86 per cent higher risk of having atrial fibrillation compared with women who had never used it or any other bisphosphonate drug. Based on the population-attributable fraction, it was estimated that 3 per cent of incident AF [atrial fibrillation] in this population could be explained by alendronate use. Careful judgment is required to weigh the risks and benefits of any medication for any individual patient, and for most women at high risk of fracture, alendronate's benefit of reducing fractures will outweigh the risk of atrial fibrillation. Although those women who are at high risk of fractures, but who are also at risk of atrial fibrillation, should talk to their doctor about alternative treatments such as oestrogen. The purpose of this study is to help medical teams to inform their patients about the risks associated with Fosamax, helping them make the best treatment decisions for managing osteoporosis.